Watch and discover more about our technology

Join our Ultivue community to receive the latest news, updates, and developments from the Ultivue team

Visualize more biomarkers and extract more insights Moving from single marker IHC to multiplex IF

Scott Lawrence - Associate Scientist, Cancer Genetics Research Group at Leidos
Katir Patel - Associate Director, Biomarker Applications at Ultivue

There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tissue tumor microenvironment. Conventional assays such as chromogenic immunohistochemistry (IHC) allow researchers to rapidly evaluate biomarker expression and staining patterns. Chromogenic IHC is often limited to single-marker same-slide staining, thus the need to stain multiple serial sections. This leads to a lack of proper cell phenotyping and spatial relationship mapping.


Using multiplex IF to uncover immune cell signatures in the TME using customizable InSituPlex assays

Scott Lawrence - Associate Scientist, Cancer Genetics Research Group at Leidos
Karan Sharma - Associate Director, Product Portfolio at Ultivue

In translational oncology research, understanding and evaluating the phenotypic profiles of cells in the tumor immune microenvironment can yield deeper understanding into the complex interactions within the immunological landscape of the tumor. Multiplex immunofluorescence can study this interplay through rapid identification, quantification, and mapping of many cell types. Having the flexibility to look for specific biological markers and their co-localization within this environment allows researchers to better understand the mechanisms of action for compounds of interest.

Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

Angela Vasaturo, PhD; Senior Scientist, Ultivue
Julia Katerina Schwarze, MD; Dept of Medical Oncology, University Hospital Brussels

In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.

Gaining key phenotypic data from the tumor microenvironment using 8-plex immunofluorescence staining and image analysis

Angela Vasaturo, PhD; Senior Scientist, Ultivue, Lorcan Sherry, PhD; Chief Science Officer, OracleBio

Broadcast via The Pathologist, November 2020. Multiplex staining and image analysis are being increasingly deployed for immuno-oncology (I/O) evaluations to investigate and unravel the complexity of immune cell/tumor cell interactions in the tumor microenvironment (TME) and in discovering novel predictive biomarkers for targeted immunotherapy. Immune checkpoint inhibitor treatment, guided by PD-L1 and PD-1 tissue expression assessed by immunohistochemistry, has already shown to improve outcomes for non-small cell lung carcinoma (NSCLC) and colorectal cancer (CRC) metastatic patients. During this webinar, we’ll present a workflow utilizing an 8-plex staining protocol and detailed image analysis approach for the comprehensive assessment of the immune cell types and interactions within the TME, including co-localization and spatial phenotyping analysis in NSCLC and CRC tumor types.

Improving the diagnostic accuracy of the PD-L1 test with multiplexing and image analysis

Angela Vasaturo, PhD; Senior Scientist, Ultivue, Matt Humphries, PhD; Tissue Hybridization Scientific Lead, Queens University Belfast

Targeting of the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis with checkpoint inhibitors has changed clinical practice in non-small cell lung cancer (NSCLC). However, clinical assessment remains complex and ambiguous. During this webinar, Matt Humphries from the Patrick G Johnson Centre for Cancer Research at Queens University, Belfast will discuss results presented in a recently published paper in the journal Cancers, “Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization.” In this study, the authors assessed whether the application of digital image analysis (DIA) and multiplex immunofluorescence to digital PD-L1 immunohistochemistry (IHC) slides has the potential to improve the accuracy and reproducibility of PD-L1 diagnostic tests.

The Scientist - Investigating Targeted CD3 Activation in Cytotoxic T cells via Immune Checkpoint Inhibition

Kristin Fino, Frederick National Laboratory for Cancer Research

Immune checkpoint inhibitors promote anti-tumor immune responses by enhancing T-cell activity. Measuring the pharmacodynamic effects of these drug types presents a challenge as both the immune and cancer cell populations must be separated and assessed individually. Using a quantitative multiplex immunofluorescence assay (mIF) allows for in-depth cell phenotype characterization and spatial context. Researchers at Frederick National Laboratory for Cancer Research developed a robust mIF assay with InSituPlex® technology to better investigate T-cell activation states within the tumor microenvironment and across multiple patient tumor biopsies.

The Pathologist - Leveraging next generation multiplex fluorescence immunohistochemistry

Alexander Klimowicz, Boehringer Ingelheim

Next-generation multiplex fluorescence immunohistochemistry methods offer new capabilities for scientists to explore the biology of disease within patient tissues.This webinar will focus on user experiences using the Ultivue InSituPlex fluorescence multiplex IHC platform and provide insight and examples of how this technology can be applied in a research setting.

Labroots - Phenotyping the Tumor Microenvironment with Advanced Tissue-Base Multiplexing Assays

Katir Patel, Ultivue

The benefits of multiplex immunohistochemistry assays for tissue analysis are numerous. This webinar will provide insight into how Ultivue’s InSituPlex® technology addresses each of these needs and current challenges to enable researchers to unmask the true biology of tissue samples.

Labroots - Multiplex fluorescence immunohistochemistry using the Ultivue InSituPlex platform

Leica Biosystems & Boehringer Ingelheim

Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease. However, the multiplexing capabilities of fluorescence IHC are subject to several technical challenges. This webinar will provide insight and examples of how the Ultivue InSituplex platform may be used to address several of the current challenges associated with multiplex fluorescence immunohistochemistry.

Contact Us